Index RUT P/E - EPS (ttm) -2.19 Insider Own 15.00% Shs Outstand 54.48M Perf Week 10.31%
Market Cap 42.22M Forward P/E - EPS next Y -1.02 Insider Trans -1.01% Shs Float 46.47M Perf Month -14.90%
Income -118.51M PEG - EPS next Q -0.40 Inst Own 48.01% Short Float 5.61% Perf Quarter 37.67%
Sales 20.97M P/S 2.01 EPS this Y 50.23% Inst Trans -0.35% Short Ratio 4.21 Perf Half Y -40.14%
Book/sh 1.05 P/B 0.74 EPS next Y 6.61% ROA -76.94% Short Interest 2.61M Perf Year -81.12%
Cash/sh 1.85 P/C 0.42 EPS next 5Y - ROE -109.80% 52W Range 0.50 - 4.67 Perf YTD 3.93%
Dividend Est. - P/FCF - EPS past 5Y -1.20% ROI -118.22% 52W High -83.46% Beta 0.81
Dividend TTM - Quick Ratio 4.43 Sales past 5Y 115.17% Gross Margin 69.32% 52W Low 54.44% ATR (14) 0.07
Dividend Ex-Date - Current Ratio 4.54 EPS Y/Y TTM -37.39% Oper. Margin -579.43% RSI (14) 50.91 Volatility 9.64% 9.43%
Employees 55 Debt/Eq 0.76 Sales Y/Y TTM -49.92% Profit Margin -565.21% Recom 1.40 Target Price 5.12
Option/Short Yes / Yes LT Debt/Eq 0.76 EPS Q/Q -5.19% Payout - Rel Volume 0.31 Prev Close 0.76
Sales Surprise -68.12% EPS Surprise -32.29% Sales Q/Q -7.88% Earnings Mar 04 AMC Avg Volume 619.17K Price 0.77
SMA20 2.92% SMA50 -7.33% SMA200 -42.90% Trades
Volume 192,930 Change 1.79%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-08-23 Downgrade BofA Securities
Neutral → Underperform
$13 → $6
Mar-08-22 Upgrade JP Morgan
Neutral → Overweight
$17 → $20
Nov-01-21 Resumed Canaccord Genuity
Buy
$33
Aug-03-21 Initiated JP Morgan
Neutral
$16
Apr-21-20 Reiterated H.C. Wainwright
Buy
$30 → $33
Aug-12-19 Reiterated H.C. Wainwright
Buy
$31 → $30
May-29-19 Reiterated Laidlaw
Buy
$26 → $32
Feb-06-19 Resumed Jefferies
Buy
$22
Jan-15-19 Initiated BofA/Merrill
Neutral
$19
Sep-21-18 Initiated Cantor Fitzgerald
Overweight
Sep-13-18 Initiated Jefferies
Buy
$30
Aug-08-18 Reiterated Stifel
Buy
$22 → $26
Jun-28-18 Reiterated H.C. Wainwright
Buy
$24 → $26
Mar-12-18 Resumed H.C. Wainwright
Buy
$22
Feb-12-18 Upgrade Janney
Neutral → Buy
Jan-19-18 Initiated Seaport Global Securities
Buy
$27
Jun-30-17 Reiterated Stifel
Buy
$24 → $20
Jun-30-17 Reiterated Laidlaw
Buy
$35 → $30
Jun-30-17 Downgrade Janney
Buy → Neutral
Mar-28-17 Reiterated Laidlaw
Buy
$20 → $35
Show Previous Ratings
Apr-02-24 07:00AM
Mar-07-24 07:00AM
06:40AM
Mar-05-24 09:07AM
07:51AM
(Thomson Reuters StreetEvents)
08:51PM
Loading…
Mar-04-24 08:51PM
05:10PM
04:21PM
(Associated Press Finance)
04:01PM
Feb-12-24 04:01PM
Jan-22-24 10:19AM
07:00AM
Dec-18-23 07:00AM
Nov-14-23 11:04AM
08:48AM
(Thomson Reuters StreetEvents)
06:00PM
Loading…
Nov-13-23 06:00PM
04:15PM
(Associated Press Finance)
04:01PM
Nov-09-23 11:38AM
Nov-06-23 10:00AM
Nov-02-23 07:00AM
Oct-23-23 07:00AM
Sep-25-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 02:53AM
Aug-08-23 05:54AM
(Thomson Reuters StreetEvents)
Aug-07-23 05:15PM
04:09PM
(Associated Press Finance)
04:01PM
Aug-03-23 07:00AM
07:00AM
Loading…
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jun-14-23 01:37PM
Jun-13-23 06:30AM
Jun-02-23 06:46PM
Jun-01-23 07:00AM
May-30-23 06:34PM
May-25-23 06:40AM
May-18-23 04:53PM
02:00AM
May-16-23 11:02AM
(Thomson Reuters StreetEvents) +7.23%
May-15-23 05:15PM
04:07PM
04:01PM
May-04-23 09:38AM
May-01-23 07:00AM
Apr-26-23 08:00PM
Apr-10-23 07:00AM
Apr-07-23 08:41AM
Mar-14-23 07:00AM
Mar-11-23 07:19AM
Mar-08-23 06:59AM
Mar-07-23 10:46AM
10:02AM
(Thomson Reuters StreetEvents)
09:43AM
08:05AM
Mar-06-23 07:39PM
05:15PM
04:01PM
Feb-27-23 10:00AM
Feb-21-23 07:00AM
Feb-15-23 05:11AM
Feb-08-23 05:00PM
Jan-17-23 07:00AM
Jan-03-23 07:00AM
Dec-29-22 05:53AM
Nov-29-22 07:30AM
Nov-09-22 06:08AM
Nov-07-22 05:35PM
04:01PM
Nov-04-22 08:46AM
Nov-03-22 07:00AM
Nov-02-22 10:01AM
07:00AM
Oct-31-22 10:00AM
Oct-30-22 08:51AM
Oct-24-22 07:00AM
Oct-18-22 09:55AM
Oct-10-22 04:05PM
Sep-28-22 07:00AM
Sep-20-22 09:47AM
Sep-12-22 07:00AM
Sep-08-22 02:27PM
08:15AM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
04:01PM
Aug-04-22 08:48AM
Aug-03-22 07:00AM
Aug-01-22 04:01PM
Jul-28-22 09:14AM
Jul-22-22 06:39AM
Jun-30-22 10:19AM
07:00AM
Jun-06-22 11:46AM
May-23-22 07:04AM
May-17-22 07:00AM
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Terrillion Scott SEC'Y; CHIEF COMPLIANCE & G.C. Apr 05 '24 Sale 0.83 2,753 2,285 88,247 Apr 09 04:21 PM Goncalves Joana CHIEF MEDICAL OFFICER Apr 05 '24 Sale 0.83 2,753 2,285 53,365 Apr 09 04:22 PM Posner Christopher PRESIDENT AND CEO Feb 29 '24 Sale 0.89 5,834 5,192 180,521 Mar 04 04:19 PM Goncalves Joana CHIEF MEDICAL OFFICER Feb 29 '24 Sale 0.89 3,293 2,931 56,118 Mar 04 04:13 PM Terrillion Scott SEC'Y; CHIEF COMPLIANCE & G.C. Feb 29 '24 Sale 0.89 3,293 2,931 91,000 Mar 04 04:24 PM Posner Christopher PRESIDENT AND CEO Feb 08 '24 Sale 0.53 35,575 18,855 186,355 Feb 12 05:10 PM Posner Christopher PRESIDENT AND CEO Feb 01 '24 Sale 0.55 4,981 2,740 221,930 Feb 05 04:26 PM Posner Christopher President and CEO Nov 02 '23 Sale 1.22 3,796 4,631 164,411 Nov 03 04:37 PM Posner Christopher President and CEO Aug 03 '23 Sale 3.07 4,307 13,222 168,207 Aug 04 05:21 PM Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D Jun 23 '23 Sale 3.51 2,993 10,505 153,747 Jun 27 04:08 PM Goncalves Joana Chief Medical Officer Jun 23 '23 Sale 3.51 2,723 9,558 53,681 Jun 27 04:07 PM Terrillion Scott Sec'y; Chief Compliance & G.C. Jun 23 '23 Sale 3.51 2,483 8,715 88,563 Jun 27 04:09 PM Posner Christopher President and CEO May 05 '23 Sale 4.40 3,869 17,024 172,514 May 09 04:22 PM
Index RUT P/E - EPS (ttm) -1.89 Insider Own 20.98% Shs Outstand 256.14M Perf Week 11.61%
Market Cap 3.60B Forward P/E - EPS next Y -0.76 Insider Trans 9.91% Shs Float 220.71M Perf Month -8.07%
Income -444.04M PEG - EPS next Q -0.42 Inst Own 66.57% Short Float 22.19% Perf Quarter 59.80%
Sales 1.19M P/S 3023.12 EPS this Y 31.49% Inst Trans -1.91% Short Ratio 5.48 Perf Half Y 237.17%
Book/sh 2.28 P/B 5.64 EPS next Y 41.26% ROA -61.49% Short Interest 48.98M Perf Year 110.11%
Cash/sh 1.00 P/C 12.85 EPS next 5Y - ROE -81.91% 52W Range 3.21 - 18.33 Perf YTD 58.43%
Dividend Est. - P/FCF - EPS past 5Y -8.25% ROI -68.03% 52W High -29.73% Beta 0.86
Dividend TTM - Quick Ratio 2.70 Sales past 5Y 0.00% Gross Margin -3091.17% 52W Low 301.25% ATR (14) 0.75
Dividend Ex-Date - Current Ratio 2.79 EPS Y/Y TTM 23.77% Oper. Margin -38734.99% RSI (14) 53.48 Volatility 5.86% 5.52%
Employees 557 Debt/Eq 0.13 Sales Y/Y TTM - Profit Margin -37345.42% Recom 1.29 Target Price 26.00
Option/Short Yes / Yes LT Debt/Eq 0.12 EPS Q/Q 28.86% Payout - Rel Volume 0.46 Prev Close 12.50
Sales Surprise -66.55% EPS Surprise -4.46% Sales Q/Q - Earnings May 09 AMC Avg Volume 8.94M Price 12.88
SMA20 5.33% SMA50 -8.60% SMA200 55.07% Trades
Volume 4,087,298 Change 3.04%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Initiated Goldman
Buy
$12
Sep-18-23 Reiterated Barclays
Overweight
$40 → $18
May-30-23 Upgrade Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated Guggenheim
Neutral
Aug-18-22 Resumed Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed Cowen
Outperform
Jun-10-21 Upgrade JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade Stifel
Buy → Hold
May-19-21 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
May-03-21 Initiated Truist
Buy
$50
Apr-16-21 Initiated Goldman
Buy
$97
Mar-08-21 Upgrade H.C. Wainwright
Neutral → Buy
$50
Dec-15-20 Downgrade H.C. Wainwright
Buy → Neutral
Oct-06-20 Downgrade Wells Fargo
Overweight → Equal Weight
Apr-22-20 Initiated Mizuho
Buy
$61
Show Previous Ratings
May-01-24 06:01AM
Apr-30-24 06:01AM
Apr-28-24 02:44PM
Apr-27-24 07:00AM
Apr-25-24 10:30AM
09:20AM
Loading…
09:20AM
Apr-24-24 04:01PM
Apr-21-24 05:08AM
Apr-19-24 05:15PM
Apr-17-24 09:45AM
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
(The Wall Street Journal)
05:30PM
Loading…
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Feb-29-24 05:47PM
12:17PM
(Thomson Reuters StreetEvents)
10:37AM
09:44AM
05:51AM
05:35PM
Loading…
Feb-28-24 05:35PM
04:42PM
(Associated Press Finance)
04:35PM
04:01PM
Feb-27-24 08:52AM
Feb-26-24 05:39AM
Feb-25-24 08:07AM
05:01AM
Feb-23-24 06:14AM
Feb-22-24 08:45AM
04:00AM
Feb-20-24 03:38PM
11:02AM
08:00AM
06:30AM
Feb-19-24 08:36AM
Feb-16-24 05:30PM
04:04PM
03:38PM
03:35PM
03:19PM
Feb-12-24 07:14AM
Feb-08-24 07:27AM
Feb-07-24 05:10AM
Feb-05-24 05:25AM
Feb-04-24 06:27AM
Jan-19-24 05:15PM
Jan-15-24 12:27PM
Jan-08-24 05:31AM
Dec-28-23 05:59PM
11:13AM
08:01AM
Dec-27-23 05:26PM
(Yahoo Finance Video) -18.67%
02:02PM
12:21PM
(Associated Press Finance)
12:21PM
11:21AM
10:41AM
09:57AM
07:06AM
07:00AM
Dec-22-23 05:15PM
Dec-18-23 02:58PM
Dec-12-23 08:45AM
05:29AM
Dec-07-23 11:31AM
Nov-20-23 12:00PM
Nov-17-23 05:00PM
Nov-08-23 05:04PM
01:03PM
07:55AM
Nov-07-23 04:26PM
(Associated Press Finance)
04:01PM
Oct-31-23 04:01PM
09:05AM
Oct-24-23 06:54AM
Oct-20-23 05:15PM
Oct-16-23 08:15AM
Sep-27-23 04:01PM
Sep-22-23 06:25PM
Sep-15-23 04:20PM
07:26AM
Sep-14-23 06:10PM
04:36PM
Sep-07-23 11:30AM
07:31AM
Aug-31-23 10:16PM
Aug-28-23 11:53PM
Aug-18-23 05:00PM
Aug-09-23 11:14AM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vogt Frederick G Interim CEO & General Counsel Apr 15 '24 Option Exercise 0.00 20,834 0 150,185 Apr 17 07:08 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Apr 15 '24 Option Exercise 0.00 2,812 0 43,989 Apr 17 07:07 PM BILINSKY IGOR Chief Operating Officer Apr 15 '24 Option Exercise 0.00 2,812 0 39,453 Apr 17 07:07 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 04 '24 Option Exercise 0.00 15,623 0 49,230 Mar 06 06:20 PM Vogt Frederick G Interim CEO & General Counsel Mar 04 '24 Option Exercise 0.00 41,662 0 140,800 Mar 06 06:19 PM Rothbaum Wayne P. Director Feb 20 '24 Buy 9.15 5,000,000 45,750,000 28,067,333 Feb 20 04:11 PM MCPEAK MERRILL A Director Feb 20 '24 Buy 9.15 250,000 2,287,500 320,150 Feb 20 07:52 PM Dukes Iain D. Director Feb 20 '24 Buy 9.15 32,000 292,800 54,000 Feb 20 04:21 PM Vogt Frederick G Interim CEO & General Counsel Jan 16 '24 Option Exercise 0.00 20,834 0 105,668 Jan 18 06:09 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jan 16 '24 Option Exercise 0.00 2,813 0 35,184 Jan 18 06:09 PM BILINSKY IGOR Chief Operating Officer Jan 16 '24 Option Exercise 0.00 2,813 0 31,444 Jan 18 06:07 PM Vogt Frederick G Interim CEO & General Counsel Oct 16 '23 Option Exercise 0.00 20,835 0 93,685 Oct 18 08:05 PM BILINSKY IGOR Chief Operating Officer Oct 16 '23 Option Exercise 0.00 2,813 0 30,026 Oct 18 08:04 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Oct 16 '23 Option Exercise 0.00 2,813 0 33,766 Oct 18 08:03 PM MCPEAK MERRILL A Director Sep 18 '23 Buy 5.56 10,000 55,600 248,633 Sep 19 04:30 PM Rothbaum Wayne P. Director Sep 15 '23 Buy 5.30 5,000,000 26,500,000 23,067,333 Sep 15 06:12 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jul 14 '23 Option Exercise 0.00 2,813 0 32,348 Jul 17 06:22 PM Vogt Frederick G Interim CEO & General Counsel Jul 14 '23 Option Exercise 0.00 20,834 0 81,701 Jul 17 06:22 PM BILINSKY IGOR Chief Operating Officer Jul 14 '23 Option Exercise 0.00 2,813 0 28,608 Jul 17 06:21 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
